CLINICAL_TRIALS
ClinicalTrials.gov record update
The SABRE Trial: A Single-arm Prospective Study Measuring Safety, Tolerability and Pharmacokinetics of Two SARS-CoV-2 Neutralising Antibodies (C135-LS and C144-LS) Amongst High-risk Special Populations of Vaccine Non-responders.
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT05393999
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:39:12.258694+00:00
- Published At
- 2023-04-24T00:00:00+00:00
- Record Updated At
- 2023-04-24
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["SARS-CoV2 Infection", "SARS-CoV-2 Acute Respiratory Disease", "Myeloma", "Leukemia", "Lymphoma", "Immune Thrombocytopenia", "Thrombotic Thrombocytopenic Purpura (TTP)"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2023-04-24"- protocolSection.identificationModule.nctId
"NCT05393999"- protocolSection.identificationModule.officialTitle
"The SABRE Trial: A Single-arm Prospective Study Measuring Safety, Tolerability and Pharmacokinetics of Two SARS-CoV-2 Neutralising Antibodies (C135-LS and C144-LS) Amongst High-risk Special Populations of Vaccine Non-responders."- protocolSection.statusModule.overallStatus
"WITHDRAWN"- protocolSection.designModule.phases
["PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.